iCo Therapeutics Inc. Announces Program And Intellectual Property...

With the recent receipt of ethics approval, the Oral AmpB technology is also moving into in vitro testing with study partners in , and will examine the role of this formulation in targeting latent HIV reservoirs which remain in individuals despite enormous therapeutic advances in the treatment of HIV/AIDS.

http://www.biospace.com/news_story.aspx?StoryID=318574&full=1